Biotech IV Monitor

NRIX — Nurix Therapeutics Inc.

$2.4B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Nurix Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2028.

Next readoutJanuary 2028in ~14 months
Upcoming readouts31 Phase 3
Market cap$2.4B
Cash & investments$1.10Bas of Aug 31, 2026
Recent 8-K filings1latest 2026-11-03

Upcoming readouts

Phase 2 NX-5948
Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) · NCT07221500
January 2028
Recruiting
Phase 3 NX-5948
B-cell Lymphoma; Chronic Lymphocytic Leukemia · NCT07516093
October 2029
Recruiting
Phase 1/2 NX-5948
B-cell Lymphoma; Chronic Lymphocytic Leukemia · NCT07520006
May 2033
Recruiting

Cash position

Nurix Therapeutics Inc. reported $1.10B in cash, cash equivalents and marketable securities at Aug 31, 2026 (10-Q filed 2026-10-13). It reported net income of $550M for that quarter.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-03

Companies working on similar indications

Discussion

No messages yet. If you follow NRIX, you can start the conversation.
Track NRIX in real time
See live implied volatility for NRIX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on NRIX
Contact — questions or corrections about NRIX: dukeupt@gmail.com